These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 28522562

  • 21. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells.
    Boerner JL, Gibson MA, Fox EM, Posner ED, Parsons SJ, Silva CM, Shupnik MA.
    Mol Endocrinol; 2005 Nov; 19(11):2660-70. PubMed ID: 15976008
    [Abstract] [Full Text] [Related]

  • 22. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha.
    Weitsman GE, Weebadda W, Ung K, Murphy LC.
    Breast Cancer Res Treat; 2009 Nov; 118(2):269-79. PubMed ID: 18941890
    [Abstract] [Full Text] [Related]

  • 23. Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells.
    Ivanova MM, Mazhawidza W, Dougherty SM, Klinge CM.
    Am J Respir Cell Mol Biol; 2010 Mar; 42(3):320-30. PubMed ID: 19556604
    [Abstract] [Full Text] [Related]

  • 24. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
    Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M.
    Cancer Res; 2007 Feb 15; 67(4):1859-66. PubMed ID: 17308128
    [Abstract] [Full Text] [Related]

  • 25. Phosphatidylinositol 3-kinase and glycogen synthase kinase 3 regulate estrogen receptor-mediated transcription in neuronal cells.
    Mendez P, Garcia-Segura LM.
    Endocrinology; 2006 Jun 15; 147(6):3027-39. PubMed ID: 16497810
    [Abstract] [Full Text] [Related]

  • 26. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
    Zhan Y, Zhang Y, Liu C, Zhang J, Smith WW, Wang N, Chen Y, Zheng L, He L.
    Cancer Prev Res (Phila); 2012 Jun 15; 5(6):864-73. PubMed ID: 22496388
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation.
    Pozo-Guisado E, Lorenzo-Benayas MJ, Fernández-Salguero PM.
    Int J Cancer; 2004 Mar 20; 109(2):167-73. PubMed ID: 14750165
    [Abstract] [Full Text] [Related]

  • 32. Specific inhibition of estrogen receptor alpha function by antisense oligodeoxyribonucleotides.
    Taylor AH, Pringle JH, Bell SC, Al-Azzawi F.
    Antisense Nucleic Acid Drug Dev; 2001 Aug 20; 11(4):219-31. PubMed ID: 11572599
    [Abstract] [Full Text] [Related]

  • 33. Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.
    Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM, Martin AL.
    Mol Cancer Ther; 2011 Nov 20; 10(11):2062-71. PubMed ID: 21862684
    [Abstract] [Full Text] [Related]

  • 34. Protein kinase A activation of estrogen receptor alpha transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation.
    Tsai HW, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA.
    Endocrinology; 2004 Jun 20; 145(6):2730-8. PubMed ID: 15033909
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Estrogen receptor alpha (ERα)-mediated coregulator binding and gene expression discriminates the toxic ERα agonist diethylstilbestrol (DES) from the endogenous ERα agonist 17β-estradiol (E2).
    Adam AHB, de Haan LHJ, Estruch IM, Hooiveld GJEJ, Louisse J, Rietjens IMCM.
    Cell Biol Toxicol; 2020 Oct 20; 36(5):417-435. PubMed ID: 32088792
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. 17β-Estradiol and/or estrogen receptor alpha blocks isoproterenol-induced calcium accumulation and hypertrophy via GSK3β/PP2A/NFAT3/ANP pathway.
    Pai P, Velmurugan BK, Kuo CH, Yen CY, Ho TJ, Lin YM, Chen YF, Lai CH, Day CH, Huang CY.
    Mol Cell Biochem; 2017 Oct 20; 434(1-2):181-195. PubMed ID: 28577190
    [Abstract] [Full Text] [Related]

  • 40. Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.
    Yang L, Huang F, Mei J, Wang X, Zhang Q, Wang H, Xi M, You Z.
    Int J Gynecol Cancer; 2017 Feb 20; 27(2):196-205. PubMed ID: 27870715
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.